What is Erste Group Bank’s Forecast for MRK FY2027 Earnings?

Merck & Co., Inc. (NYSE:MRK) – Stock analysts at Erste Group Bank boosted their FY2027 earnings estimates for shares of Merck & Co., Inc. in a report issued on Tuesday, May 12th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $9.66 for the year, up from their prior forecast of $9.62. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $5.16 per share.

Other research analysts have also recently issued research reports about the stock. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. UBS Group lifted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Barclays assumed coverage on Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price target on the stock. Finally, Guggenheim lifted their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Trading Down 0.2%

MRK stock opened at $113.21 on Friday. The business has a fifty day moving average price of $116.18 and a 200 day moving average price of $109.19. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The stock has a market capitalization of $279.60 billion, a price-to-earnings ratio of 31.89, a P/E/G ratio of 2.55 and a beta of 0.18. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the fourth quarter worth $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. during the 4th quarter worth $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. during the fourth quarter worth about $26,000. United Financial Planning Group LLC bought a new position in Merck & Co., Inc. during the third quarter worth about $31,000. Finally, High Note Wealth LLC grew its stake in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.